Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

By sjmartinez • April 23, 2024

Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60. Dermatol Ther (Heidelb). 2024 Apr 22. doi: 10.1007/s13555-024-01147-7. Epub ahead of print. PMID: 38647975.

Tags: Clinical outcomes, Dermatology, ixekizumab, long-term, patient-reported outcomes, psoriasis, Publications, Quality of Life, Scalp clearance

Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOST

Coates LC, Gladman DD, Merola JF, Mrowietz U, Armstrong A, Baraliakos X, Tillett W, Kishimoto M, Reddy J, Teng L, Amouzadeh H, Deignan C, Mease[...]

GRAPPA 2025 Annual Meeting Report: Session on Geographic Variations in Psoriatic Arthritis/Psoriasis Care and Resource Limitations

Ma EJ, Boit R, Leung YY, Singla S, Fernández-Ávila D, Kalyoncu U, Armstrong AW. GRAPPA 2025 Annual Meeting Report: Session on Geographic Variations in Psoriatic[...]

Paradoxical melanoma in situ arising in a depigmented patch secondary to immunotherapy

Shah KS, Kang Y, Opene C. Paradoxical melanoma in situ arising in a depigmented patch secondary to immunotherapy. JAAD Case Rep. 2026 May 15;74:115-117. doi:[...]